295 related articles for article (PubMed ID: 31476872)
21. Effect of Ramadan intermittent fasting on inflammatory markers, disease severity, depression, and quality of life in patients with inflammatory bowel diseases: A prospective cohort study.
Negm M; Bahaa A; Farrag A; Lithy RM; Badary HA; Essam M; Kamel S; Sakr M; Abd El Aaty W; Shamkh M; Basiony A; Dawoud I; Shehab H
BMC Gastroenterol; 2022 Apr; 22(1):203. PubMed ID: 35462542
[TBL] [Abstract][Full Text] [Related]
22. Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.
Kalla R; Kennedy NA; Ventham NT; Boyapati RK; Adams AT; Nimmo ER; Visconti MR; Drummond H; Ho GT; Pattenden RJ; Wilson DC; Satsangi J
Am J Gastroenterol; 2016 Dec; 111(12):1796-1805. PubMed ID: 27596694
[TBL] [Abstract][Full Text] [Related]
23. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
24. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission.
Falvey JD; Hoskin T; Meijer B; Ashcroft A; Walmsley R; Day AS; Gearry RB
Inflamm Bowel Dis; 2015 Apr; 21(4):824-31. PubMed ID: 25738372
[TBL] [Abstract][Full Text] [Related]
25. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease.
Penna FGC; Rosa RM; Pereira FH; Cunha PFS; Sousa SCS; Ferrari TCA; Cara C; Ferrari MLA
Gastroenterol Hepatol; 2021 Feb; 44(2):87-95. PubMed ID: 32680729
[TBL] [Abstract][Full Text] [Related]
26. Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy.
Engström J; Lönnkvist M; Befrits R; Ljung T; Diaz-Tartera H; Holst M; Hellström PM
Scand J Gastroenterol; 2019 Sep; 54(9):1081-1088. PubMed ID: 31499013
[No Abstract] [Full Text] [Related]
27. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
Carlsen K; Riis LB; Elsberg H; Maagaard L; Thorkilgaard T; Sørbye SW; Jakobsen C; Wewer V; Florholmen J; Goll R; Munkholm P
Scand J Gastroenterol; 2018; 53(7):825-830. PubMed ID: 29968483
[TBL] [Abstract][Full Text] [Related]
28. Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis.
Brandse JF; Bennink RJ; van Eeden S; Löwenberg M; van den Brink GR; DʼHaens GR
Inflamm Bowel Dis; 2016 Jun; 22(6):1384-90. PubMed ID: 26978724
[TBL] [Abstract][Full Text] [Related]
29. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
[TBL] [Abstract][Full Text] [Related]
30. Rapid fecal calprotectin test for prediction of mucosal inflammation in ulcerative colitis and Crohn disease: a prospective cohort study.
Moniuszko A; Głuszek S; Rydzewska G
Pol Arch Intern Med; 2017 May; 127(5):312-318. PubMed ID: 28442699
[TBL] [Abstract][Full Text] [Related]
31. The Toronto IBD Global Endoscopic Reporting [TIGER] Score: A Single, Easy to Use Endoscopic Score for Both Crohn's Disease and Ulcerative Colitis Patients.
Zittan E; Steinhart AH; Aran H; Milgrom R; Gralnek IM; Zelber-Sagi S; Silverberg MS
J Crohns Colitis; 2022 May; 16(4):544-553. PubMed ID: 34272937
[TBL] [Abstract][Full Text] [Related]
32. Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use.
Subramanian S; Asher R; Weston W; Rimmer M; McConville A; Malin A; Jackson R; Collins P; Probert C; Dibb M; Rhodes JM
Inflamm Bowel Dis; 2016 Aug; 22(8):1902-7. PubMed ID: 27243590
[TBL] [Abstract][Full Text] [Related]
33. GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD.
Dierckx T; Verstockt B; Vermeire S; van Weyenbergh J
J Crohns Colitis; 2019 Mar; 13(3):389-394. PubMed ID: 30312386
[TBL] [Abstract][Full Text] [Related]
34. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study.
Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY
Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068
[TBL] [Abstract][Full Text] [Related]
35. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity.
Lee YW; Lee KM; Lee JM; Chung YY; Kim DB; Kim YJ; Chung WC; Paik CN
Korean J Intern Med; 2019 Jan; 34(1):72-80. PubMed ID: 29347813
[TBL] [Abstract][Full Text] [Related]
36. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
Aliment Pharmacol Ther; 2016 May; 43(10):1069-79. PubMed ID: 26953251
[TBL] [Abstract][Full Text] [Related]
37. Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin.
Zubin G; Peter L
Inflamm Bowel Dis; 2015 Jun; 21(6):1386-91. PubMed ID: 25851564
[TBL] [Abstract][Full Text] [Related]
38. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis.
Rokkas T; Portincasa P; Koutroubakis IE
J Gastrointestin Liver Dis; 2018 Sep; 27(3):299-306. PubMed ID: 30240474
[TBL] [Abstract][Full Text] [Related]
39. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
[TBL] [Abstract][Full Text] [Related]
40. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease.
Abej E; El-Matary W; Singh H; Bernstein CN
Can J Gastroenterol Hepatol; 2016; 2016():2483261. PubMed ID: 27774443
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]